Year-end Sale % OFF 
Abstract
A number of cancer vaccine strategies have entered initial Phase I clinical testing. In this review, Dr. Glenn Dranoff discusses the prospects that appropriate immunologic monitoring of patients in these trials can help delineate important differences among the various immunization strategies and prioritize the most promising approaches for further clinical development.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
